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Background
Recent studies reported that methotrexate (MTX),
appears beneficial in juvenile localized scleroderma (JLS)
but little is known about its long-term efficacy. We
assessed the long-term efficacy of MTX in a cohort of
patients with JLS.
Methods
We prospectively followed a cohort of patients with JLS
who were enrolled in a double-blind, randomized con-
trolled trial. Oral MTX was used at a dose of 15 mg/m
2
once a week (max 20 mg) for at lest 24 months; predni-
sone (1 mg/Kg/day, max 50 mg), in a single morning
dose for 3 months was added. A target lesion was evalu-
ated clinically, with infrared thermography and using a
computerized scoring system with skin score rate (SSR)
evaluation. Response to treatment was defined as: no
new lesions; SSR<1; decrease lesion temperature by at
least 10% compared to baseline. Treatment failure was
defined by new lesions, SSR>1, or increased lesion tem-
perature. Partial Remission (PR) was defined when the
state of responder was maintained ON treatment for at
least 6 months, complete remission (CR) the state of
responder OFF treatment for at least 6 months.
Results
65 patients have been treated with MTX during the
open-label phase of the study. Seven patients were lost
to follow-up. Of the remaining 58 patients, after a mean
follow-up of 43 months (median 36; range 6-72 mesi),
48 (82.8%) were responders, 10 (17.2%) relapsed by 24
months since MTX start. Among the responders, 35
(60.4%) after a MTX treatment for 27.5 months (median
24, range 18-30) maintained CR for 25 months (median
24, range 2-48). None of those in CR relapsed. 13
patients (22.4%), after a mean follow-up of 20.5 months
(median 15.5, range 6-45), were in PR.
Conclusion
Methotrexate shows a prolonged efficacy in patients
with JLS.
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